NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Omega-3 Recommendations Updated: High-Dose Icosapent Ethyl for High-Risk Patients
Photo: Depositphotos
Sep 17, 2025, 10:10

Omega-3 Recommendations Updated: High-Dose Icosapent Ethyl for High-Risk Patients

European Atherosclerosis Society has shared a post on LinkedIn:

“The recommendation for the use of omega 3 polyunsaturated fatty acids from 2019 has changed in the Focussed Update by now explicitly stating that only high-dose icosapent ethyl should be considered for high-risk or very high-risk patients with elevated triglyceride levels.

The rationale for this revision was the negative STRENGTH trial which failed to demonstrate benefit of a combined EPA and DHA preparation which is in contrast to the REDUCE-it trial which showed a reduction in cardiovascular events in high risk patients with TG levels of 1,5-5,6 mmol/L with icosapent ethyl which is a pure EPA compound.

Moreover there is a new recommendation for patients with severe hypertriglyceridaemia due to familial chylomicronaemia syndrome based on the results of the randomized placebo controlled APPROACH trial which showed a 77% decrease in TG levels and reduction of pancreatitis in FCS patients treated with Volanesorsen an antisense Oligoligonucleotide targeting apoC3.

This led to the recommendation that volenasoren should be considered in FCS patients with severe hypertriglyceridemia to lower triglyceride levels and reduce the risk of pancreatitis.”

Learn more here.

Discover more on Hemostasis Today.

Cardiology EAS ESC European Atherosclerosis Society Health Hematology Hemostasis Hemostasis Today Hypertriglyceridemia Icosapent Ethyl Lipid Management Medicine Omega3 Triglycerides
NewsFeed